Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM98VFW)

Drug Name
A-286982 Drug Info
Synonyms
A-286982; 280749-17-9; UNII-5I8WFS075A; A 286982; CHEMBL19677; 5I8WFS075A; C24H27N3O4S; (2E)-1-(4-Acetyl-1-piperazinyl)-3-[4-[[2-(1-methylethyl)phenyl]thio]-3-nitrophenyl]-2-propen-1-one; SCHEMBL5829786; GTPL6592; SCHEMBL12063498; AOB1772; SYN5060; MolPort-023-277-110; ZINC602716; BDBM50092956; AKOS024458044; API0010263; Piperazine, 1-acetyl-4-((2E)-3-(4-((2-(1-methylethyl)phenyl)thio)-3-nitrophenyl)-1-oxo-2-propenyl)-; (E)-1-(4-acetylpiperazin-1-yl)-3-[3-nitro-4-(2-propan-2-ylphenyl)sulfanylphenyl]prop-2-en-1-one; AS-16426
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9846729
CAS Number
CAS 280749-17-9
TTD Drug ID
DM98VFW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Approved Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Integrin beta-2 (ITGB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RP-L201 DMKVMWO Leukocyte adhesion deficiency type 1 4A00.0Y Phase 1/2 [4]
BMS-587101 DMS2IC9 Psoriasis vulgaris EA90 Discontinued in Phase 2 [5]
UK-279,276 DM4FZWP Stroke 8B20 Discontinued in Phase 2 [6]
MLN-2201 DMQA5JW Cerebrovascular ischaemia 8B1Z Discontinued in Phase 1 [7]
Drug(s) Targeting Integrin alpha-L (ITGAL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
lifitegrast DM4WVC5 Dry eye disease 9E1Z Approved [8]
Efalizumab DMCKL5V Psoriasis vulgaris EA90 Approved [9]
BMS-587101 DMS2IC9 Psoriasis vulgaris EA90 Discontinued in Phase 2 [10]
IC-747 DM1LVRP Psoriasis vulgaris EA90 Discontinued in Phase 2 [11]
Cytolin DMV8APG Human immunodeficiency virus infection 1C62 Preclinical [12]
Leukotoxin DMYX2NJ Autoimmune diabetes 5A10 Investigative [13]
LFA703 DM5G307 Discovery agent N.A. Investigative [14]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Targeting ICAM1 messenger RNA (ICAM1 mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ISIS 1570 DMJ9G23 Lleum inflammation 1A40.0 Approved [15]
Alicaforsen DMQ509J Lleum inflammation 1A40.0 Phase 3 [16]
INXC-ICAM1 DMODQW0 Transplant rejection NE84 Terminated [17]
ISIS 11159 DM9V6FW Discovery agent N.A. Investigative [18]
ISIS 3224 DMAFEYG Discovery agent N.A. Investigative [18]
ISIS 1931 DMBMQNI Discovery agent N.A. Investigative [15]
PIPERROLEIN B DMRVHWZ Discovery agent N.A. Investigative [19]
ISIS 2974 DM7K19L Discovery agent N.A. Investigative [15]
Dehydropipernonaline DMIOA9M Discovery agent N.A. Investigative [19]
ISIS 3067 DMC9OL7 Discovery agent N.A. Investigative [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ICAM1 messenger RNA (ICAM1 mRNA) TTA1L39 ICAM1_HUMAN Inhibitor [2]
Integrin alpha-L (ITGAL) TT48WR6 ITAL_HUMAN Inhibitor [2]
Integrin beta-2 (ITGB2) TTIJWR7 ITB2_HUMAN Inhibitor [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6592).
2 Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5269-73.
3 Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism o... J Med Chem. 2001 Apr 12;44(8):1202-10.
4 Clinical pipeline report, company report or official report of Rocket Pharmaceuticals.
5 Discovery and development of 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl-methyl]-3-thioph... J Med Chem. 2006 Nov 30;49(24):6946-9.
6 Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs. 2007 Mar;12(1):97-112.
7 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010178)
8 Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402.
9 [Successful therapy of discoid lupus erythematosus with efalizumab]. Hautarzt. 2010 Mar;61(3):246-9.
10 Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-(... J Med Chem. 2010 May 13;53(9):3814-30.
11 HECA-452+ T Cells Migrate Through Superficial Vascular Plexus but Not Through Deep Vascular Plexus Endothelium. Journal of Investigative Dermatology. 04/1997; 108(3):343-8.
12 Cytokine-induced phagocyte adhesion to human mesangial cells: role of CD11/CD18 integrins and ICAM-1. Am J Physiol. 1991 Dec;261(6 Pt 2):F1071-9.
13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2451).
14 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
15 US patent application no. 6,300,491, Oligonucleotide inhibition of cell adhesion.
16 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
17 ISIS 2302. INXC ICAM1, Oligo-TCS. Drugs R D. 1999 Jan;1(1):85-6.
18 US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
19 Alkamides from the fruits of Piper longum and Piper nigrum displaying potent cell adhesion inhibition. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4544-6.